Role of Intravitreal Antivascular Endothelial Growth Factor Injections for Choroidal Neovascularization due to Choroidal Osteoma. (23rd July 2014)

• Record Type: Journal Article
• Authors: Mansour, Ahmad M.; Arevalo, J. Fernando; Al Kahtani, Eman; Zegarra, Hernando; Abboud, Emad; Anand, Rajiv; Ahmadieh, Hamid; Sisk, Robert A.; Mirza, Salman; Tuncer, Samuray; Navea Tejerina, Amparo; Mataix, Jorge; Ascaso, Francisco J.; Pulido, Jose S.; Guthoff, Rainer; Goebel, Winfried; Roh, Young Jung; Banker, Alay S.; Gentile, Ronald C.; Martinez, Isabel Alonso; Morris, Rodney; Panday, Neeraj; Min, Park Jung; Mercé, Emilie; Lai, Timothy Y. Y.; Massoud, Vicky; Ghazi, Nicola G.
• Other Names: Baba Takayuki Academic Editor.
• Is Part Of: Journal of ophthalmology. Volume 2014(2014)
• Publication Date: 2014-07-23
• Subjects: Ophthalmology -- Periodicals; Eye Diseases; Ophthalmology; Ophthalmology; Electronic journals; Periodicals; Periodicals; Fulltext; Internet Resources; Periodicals; 617.7
• DOI: 10.1155/2014/210458
• Languages: English
• ISSNs: 2090-004X

Abstract

Abstract : We treated 26 eyes of 25 young patients having a mean age of 30 years with intravitreal vascular endothelial growth factor (VEGF) inhibitor for choroidal new vessel (CNV) formation overlying choroidal osteoma over a mean follow-up of 26 months. Mean number of injections was 2.4 at 6 months, 3.2 at 12 months, and 5.5 at 24 months. CNV was subfoveal in 14 eyes, juxtafoveal in 5, extrafoveal in 5, and peripapillary in 2. By paired comparison, mean decrease from baseline was 119.7 microns at 6 months (n = 15 ; P = 0 . 001 ), 105.3 microns at 1 year (n = 10 ; P = 0 . 03 ), and 157.6 microns at 2 years (n = 7 ; P = 0 . 08 ). BCVA improved by 3.3 lines at 6 months after therapy (n = 26 ; P < 0 . 001 ), 2.8 lines (n = 20 ; P = 0 . 01 ) at 1 year, and 3.1 lines (n = 13 ; P = 0 . 049 ) at 2 years. We conclude that intravitreal anti-VEGF injections improve vision in majority of eyes with CNV from choroidal osteoma.